MARCH 15-16, 2018 PARIS PALAIS BRONGNIART. An event of PROGRAM
|
|
|
- Calvin Weaver
- 6 years ago
- Views:
Transcription
1 MARCH 15-16, 2018 PARIS PALAIS BRONGNIART An event of PROGRAM
2 DIAGNOSIS - March 15, 12:15-13:15 Precision diagnostic: genomics plans panorama French genomic national plan: PFM2025 England Genome: genomes program European genome program And with healthcare professionals & industrial vision - March 15, 09:45-10:45 Round Table: Biology today versus tomorrow SIDIV (French Industrial in Vitro union) and SBD (French Biologist s union) overview ( biology and genetic laboratory point of view) Legal Approach - Cerba Vision - March 16, 12:00-13:00 Round Table: The point-of-care diagnostic : Major issues Introduction: New challenges (pharmaceutical industry point of view) SMEs pitches - March 15, 13:30-14:30 Diagnosis and microfluidic The European microfluidic platform presentation SMEs pitches and demonstrations - March 16, 09:30-10:30 Diagnostic companion Presentation of the European project: CODEX4SMEs SMEs pitches and demonstration
3 IMAGING - March 15, 11:00-12:00 Medical Imaging 2030 Imaging in Precision Medicine of the Future Precision Medicine of the Future: The role of Imaging Global perspective: Trends, key issues, transformations, challenges and opportunities The changing role of the Radiologist and Interventionalist in the digital era Medical imaging 2030: Enabling/disruptive technologies Imaging data banks and cohorts key issues in population imaging, radiomics and artificial intelligence - March 15, 13:30-14:30 Artificial Intelligence in medical imaging: Transformation or evolution - March 16, 09:30-10:30 From augmented imaging to mixed-reality cockpit - March 15, 17:15-18:15 Program currently in development - March 16, 10:45-11:45 Image guided-therapies
4 ADVANCED AND INNOVATIVE THERAPIES - March 15, 14:45-15:45 Therapeutic approaches Microbiome CAR-T cells Gene therapy and gene editing Emerging technologies in immunology - March 15, 17:15-18:15 Cell and gene therapy - Genopôle and other SMEs Current and future opportunities in cell and gene therapy Round table / pitches - March 16, 10:45-11:45 Breakthrough innovations in Tissue Engineering & Biomaterials Round table / pitches Instituts Carnot / Findmed Presentation - March 15, 12:15-13:15 Breakthrough innovations in bioproduction Round table / pitches - March 16, 09:30-10:30 Breakthrough innovations in oncology Round table / pitches PARIS - PALAIS BRONGNIART
5 E-HEALTH - March 15, 09:45-10:45 Artificial Intelligence: Predictive medicine Industrial and clinical point of views - March 15, 12:15-13:15 Clinical digital pathways for chronic patients Testimonials, tools, solution deployments - March 16, 13:30-14:30 Digital to improve healthcare performance Mobility testimonials Start-ups and SMEs pitches - March 15, 16:00-17:00 European market access for digital health National investment plans (Syntec study) European project (In Demand) - March 15, 17:15-18:15 Augmented and virtual reality in healthcare Global overview (SimForHealth) Start-ups and SMEs pitches
6 TALENT - March 15, 16:00-17:00 The influence of Artificial Intelligence and Big Data on skills issues ANIMATION - March 15, 09:45-19:30 Hackathon results and findings Virtual Simulation ANIMATION - March 16, 09:30-13:30 Hackathon results and findings Virtual Simulation - March 15, 11:00-12:00 Talent Acquisition with Big Data and IA IBM solutions - March 15, 13:30-14:30 Start up culture: How to develop an innovative project in healthcare European cluster/ Sanofi - March 16, 09:30-10:30 Table ronde Etude Compétences Innovation en Santé - Session in French
7 EUROPE - March 15, 13:30-14:30 How to tackle the burden of European ageing population on the healthcare system sustainability prevention and prediction as a clue - March 15, 11:00-12:00 EIT Health Network and Opportunities: Campus & Accelerator - March 15, 16:00-17:00 European champions SMEs from Paris Region CONFERENCE - March 15 09:45-10:45 Access key innovation hubs: US, Canada and Israel 13:30-14:30 Navigate through European funding programs: SMEs instrument, H2020, Eurostars, IMI 14:45-15:45 EIT Health accelerator programmes for entrepreneurs & SMEs 16:00-17:00 EIT Health Living lab & test beds network in Europe ANIMATION - March 15 & 16 Discover «LA CORBEILLE» sessions lead by EIT Health and dedicated to European startups, SMEs (MedTech, DigitalHealth, BioTech) and investors. How European SMEs and start-ups can access to cross boarder funding and mentoring in order to scale-up their development? *Access to Mentors & experts *Access to Funding *Access to Finance
8 An event of
E&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015
E&T objectives in evolving pharma business models Magda Chlebus Director Science Policy Brussels, 2 March 2015 Education adapted to demand? Declining number of students choosing science Education still
BIOTECH IN FRANCE. key info in. points
BIOTECH IN FRANCE 10 key info in points 1 2 3 INSERM: EUROPE S #1 ACADEMIC BIOTECH RESEARCH INSTITUTE INSERM spearheads healthcare and medical research in France, filing more biotech patents with the European
TAIWAN. Who Should Attend? Endless Potential & Opportunities. Where innovations are shaping a new era of intelligent healthcare.
TAIWAN Where innovations are shaping a new era of intelligent healthcare World-class medical centers and hospitals Over 1800 biotech companies Best healthcare system in the world Top-ranked life science
CCTG initiative. patient reported outcomes (including wearables)
Executive Summary Canada can be a global leader in the next generation of pharmaceutical and cancer care innovation. The Canadian Cancer Trials Group (CCTG) is requesting $39 million in federal funding
Overview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017
FNR Overview of the Luxembourg biomedical and health research ecosystem FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017 Research in Luxembourg Luxembourg : a young research location Creating structures
The International Consortium for Personalised Medicine
The International Consortium for Personalised Medicine Mairead O Driscoll Alliance for Biomedical Research in Europe, 8 November 2017 Personalised Medicine A definition Characterisation of individuals
NETWORKING AND CUREACCELERATOR LIVE!
RARE DRUG DEVELOPMENT SYMPOSIUM A PARTNERSHIP BETWEEN PENN MEDICINE ORPHAN DISEASE CENTER AND GLOBAL GENES PHILADELPHIA, PENNSYLVANIA NETWORKING AND CUREACCELERATOR LIVE! CureAccelerator Live! Rare Disease
Type of Activity. Universal Activity Number L04-P
Below are the pharmacy designated Universal Activity Numbers (UANs) and type of activity that is applicable for each of the following program offerings Session # Title 104 Impact of Biologics, Vaccines,
I. Company Information
Please fill out this form as completely as possible. Note: There is no fee to apply. Please send additional materials such as your pitch deck and executive summary to resi@lifesciencenation.com for us
I. Company Information
Please fill out this form as completely as possible. Note: There is no fee to apply. Please send additional materials such as your pitch deck and executive summary to resi@lifesciencenation.com for us
11% of employees are dedicated to R&D. 11 billions IVD market size 3,000 companies 75,000 people employed. 40,000 IVD products
About edma EDMA The European Diagnostic Manufacturers Association is an international, non-profit organisation representing the interests of the European in vitro diagnostics industry at the European and
A whole-system approach to delivering personalised medicine and health in Leeds. Mike Messenger
A whole-system approach to delivering personalised medicine and health in Leeds Mike Messenger Capacity and Resource What is the challenge? In 2016, we face the most significant challenges for a generation.
I. Company Information
If your company won (1st-3rd place) an Innovation Challenge since RESI JPM 2018, or were a finalist at RESI NYC 2018, you do not qualify to participate in the Innovation Challenge at RESI JPM 2019. Please
BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board of the development of an NHS England Personalised Medicine Strategy.
Paper: PB.24.09.15/05 Title: Personalised Medicine Strategy. From: Sir Bruce Keogh, National Medical Director. BOARD PAPER - NHS ENGLAND Purpose of Paper: To inform the Board of the development of an NHS
REIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
HIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN POINTS
HIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN 10 POINTS 1 67 BILLION IN REVENUES The biotech-medtech industry accounted for around 330,000 direct and indirect jobs and 67 billion in sales in 2016
I. Company Information
Please fill out this form as completely as possible. Note: There is no fee to apply. Please send additional materials such as your pitch deck and executive summary to resi@lifesciencenation.com for us
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
STRAND NGS 3.0 ALLOWS USERS TO ANALYZE DATA AT NEARLY TWICE THE SPEED
bio chat STRAND NGS 3.0 ALLOWS USERS TO ANALYZE DATA AT NEARLY TWICE THE SPEED The Bangalore based Strand Life Sciences has been recently in news for the back to back launch of two innovative products.
GUIDE HEA
Companies are often overwhelmed by the field of digital health. From digital and med device companies to biotechnology and pharmaceutical companies, there is a struggle to cut through the noise of numerous
Promoting the Biotechnology Industry in Germany
Positions Promoting the Biotechnology Industry in Germany Germany s biotechnology industry ranks among the most sustainable and forward looking of today s cutting-edge technologies. Biotechnology is about
TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
The Future of Clinical and Pharmaceutical Research
The Future of Clinical and Pharmaceutical Research Petra Streng, Industry Business Unit Life Sciences, SAP AG Dr. René Fitterer, Public Services & Healthcare, SAP (Switzerland) Inc. SAP Forum Basel, 20
STRATEGIC PLAN ( ) UCSD SSPPS 5/4/18 La Jolla, CA
STRATEGIC PLAN (2017 2022) 0 UCSD SSPPS 5/4/18 La Jolla, CA TABLE OF CONTENTS Message From The Dean... 1 Strategic Plan Overview, Mission, Vision and Values... 2 Background... 3 Executive Summary... 4
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
STRATEGIC PLAN ( ) UCSD SSPPS 6/1/18 La Jolla, CA
STRATEGIC PLAN (2017 2022) 0 UCSD SSPPS 6/1/18 La Jolla, CA TABLE OF CONTENTS Message From The Dean... 1 Strategic Plan Overview, Mission, Vision and Values... 2 Background... 3 Executive Summary... 4
Genomic Medicine in France
Genomic Medicine in France Catherine Nguyen, PhD Director ITMO GGB Genetic, Genomic & Bioinformatic Advancing Disease Modeling in Animal-Based research in Support of Precision Medecine: a Workshop ILAR
L A B O R M A R K E T B R I E F I N G S S E R I E S
L A B O R M A R K E T B R I E F I N G S S E R I E S LABOR MARKET INFORMATION FOR RESEARCHERS THE LIFE SCIENCE AND PHARMACEUTICALS SECTOR IN EUROPE L I F E S C I E N C E A N D P H A R M A C E U T I C A
Precision Medicine Catapult
Precision Medicine Catapult Building on UK excellence - Growing the precision medicine industry April 2015 catapult.org.uk @PMCatapult Precision Medicine Catapult scale, quality, speed National innovation
LEEDS CITY REGION DIAGNOSTICS AND PERSONALISED MEDICINE
LEEDS CITY REGION DIAGNOSTICS AND PERSONALISED MEDICINE LEEDS CITY REGION S STRENGTHS: LIFE SCIENCES - THE OPPORTUNITY TAP INTO WORLD-LEADING RESEARCH FROM LEEDS CITY REGION S UNIVERSITIES ACCELERATING
A French Biotechnology company dedicated to the development and production of human endocrine cell lines. Innovation In Healthcare April 2012
A French Biotechnology company dedicated to the development and production of human endocrine cell lines Innovation In Healthcare 16-17 April 2012 1 French Biotechnology company Founded in S2 2004 in Paris
Precision Medicine. Presented by:
Precision Medicine Presented by: Prepared Brendan FitzGerald For: Enabling better health through information technology. Healthcare Information and Management Systems Society (HIMSS) HIMSS is a global,
Course Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
The experience of Andalusia in ehealth and big data --- Big data in health - IMI s HARMONY project, European Parliament, Brussels, 19 June 2018
The experience of Andalusia in ehealth and big data --- Big data in health - IMI s HARMONY project, European Parliament, Brussels, 19 June 2018 Joaquín Dopazo Área de Bioinformática, Fundación Progreso
The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016
The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016 Marianne Kock, Head of Global Regulatory Affairs & Managing Director, Ferring Pharmaceuticals
The Canadian Digital Supercluster. Overview Presentation October 25, 2017
The Canadian Digital Supercluster Overview Presentation October 25, 2017 1 Data is absolutely the right opportunity at the right time for our ecosystem 2 1. Data is a Growing Resource 1011 0010 0.5% 2.5
The role of patients in clinical research
Biopeople Newsletter April: The role of patients in clinical research Pitch your life sc...page 1 of 10 Biopeople Newsletter April 2018 The role of patients in clinical research What is the place of patients
EU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
Investments in the Life Sciences
Investments in the Life Sciences where how why June 4 th, 2014 Horst Domdey History of the Munich Biotech Cluster 1984 Foundation of the Munich Gene Center 1989 1 st Munich biotech company 1996 Munich
Accelerating Precision Medicine with High Performance Computing Clusters
Accelerating Precision Medicine with High Performance Computing Clusters Scalable, Standards-Based Technology Fuels a Big Data Turning Point in Genome Sequencing Executive Summary Healthcare is in worldwide
Imaging Systems. Gene Saragnese CEO Imaging Systems
Growth from the Core: Imaging Systems Gene Saragnese CEO Imaging Systems Imaging g Markets 2009 Imaging Markets by Region Total EUR 14.2B 1700 900 350 1550 2300 Other emerging LATAM India Greater China
Konica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion
News Release Konica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion Advances Konica Minolta strategy to establish a leadership position in precision medicine Contributes
Commercialising Genomic Research 1-3 October 2018
Course Programme Commercialising Genomic Research 1-3 October 2018 Wellcome Genome Campus Hinxton, Cambridge, UK Monday 1 October 2018 09:30-10:00 Registration with refreshments 10:00-10:30 Introduction
NORDIC LIFE SCIEN SWEDEN S LIFE SCIENCE STRATEGY ANTIBIOTIC RESISTANCE THE LEADING LIFE SCIENCE BUSINESS MAGAZINE 169 SEK / 20 EUR / 25 USD
NORDIC LIFE SCIEN THE LEADING LIFE SCIENCE BUSINESS MAGAZINE 169 SEK / 20 EUR / 25 USD // UMEÅ // KUOPIO // TROMSØ ANTIBIOTIC RESISTANCE SWEDEN S LIFE SCIENCE STRATEGY ILLUSTRATION AJAK ARCHITECTS ALL
EU Big Data Initiatives
European Network of Excellence for Big Data in Hematology, consisting of 51 partners from 11 countries. Aliki Taylor, HARMONY Alliance Partner Director Global Health Outcomes, Takeda EU Big Data Initiatives
Artificial intelligence A CORNERSTONE OF MONTRÉAL S ECONOMIC DEVELOPMENT
Artificial intelligence A CORNERSTONE OF MONTRÉAL S ECONOMIC DEVELOPMENT What is artificial intelligence and what are its applications? Artificial intelligence (AI) is booming in Montréal. In fact, intelligent
- OMICS IN PERSONALISED MEDICINE
SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary
The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England
The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.
Topic: Genome-Environment Interactions in Inflammatory Skin Disease
Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be
Regulatory and Reimbursement Obstacles Clinical Update of Molecular Diagnostics ASU
Regulatory and Reimbursement Obstacles Clinical Update of Molecular Diagnostics ASU Bruce Quinn MD PhD Bruce. Quinn @ faegrebd. com 323 839 8637 mobile April 8, 2016 Sky Song / Scottsdale Digital Health
The Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
Konica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
New Health Data Economy: Strategic Partnerships with Life Sciences Company
New Health Data Economy: Strategic Partnerships with Life Sciences Company Pravin R Jadhav Sr. Director, Innovative Data Solutions Otsuka Data Sciences Otsuka Pharmaceutical Development and Commercialization
Module: Key Enabling Technologies for Biomedical Engineering
Module: Key Enabling Technologies for Biomedical Engineering Mandatory Courses New Frontiers in Medical Technology Coordinator: Laura González Credits: 6 This course offers an up-to-date report on current
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS 2018-2024 ORACLE 2.0: Leading Globally, from Innovation to Impact P1 P2 NOTE FROM OUR LEADERS NOTE FROM VP RESEARCH,
Personalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative
The Learning Pharmacovigilance System
The Learning Pharmacovigilance System From Concept to Reality In pharmacovigilance, intelligent should be able to identify new & previously unknown drug safety issues early enough to prevent significant
Fostering Convergent Scientific Research and Industry Engagement in a University Setting: Challenges and Strategies
Fostering Convergent Scientific Research and Industry Engagement in a University Setting: Challenges and Strategies Colin Duckett, Ph.D. Professor, Departments of Pathology & Internal Medicine Director,
A bold vision for 2025
Leading the Biomedical Revolution in Precision Health: How Stanford Medicine is Developing the Next Generation of Health Annual Stanford Medicine Population Health Sciences Colloquium October 26, 2015
Bavarian Biotech Inside Shaping the Future of Medicine.
Bavarian Biotech Inside Shaping the Future of Medicine Bio M accelerating biomedical innovation Vision Bavaria the place for the medicine of the future Mission Bio M recognizes the challenges of the medicine
Innovation and Technology in Breast Cancer 2019 A research initiative from Breast Cancer Foundation NZ.
Request for Proposals Innovation and Technology in Breast Cancer 2019 A research initiative from Breast Cancer Foundation NZ. Overview Breast Cancer Foundation NZ (BCFNZ) is committed to funding research
A gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
Pharmaceuticals and Biotechnology
ABCD Pharmaceuticals and yet are quickly accessible from one central location. 7 Gain a competitive advantage 7 Facilitate product research and development 7 Raise return on investment Pharmaceuticals
The Innovative Medicines Initiative. Pierre Meulien CNIO, Madrid - Spain
The Innovative Medicines Initiative Pierre Meulien 12.01.2017 CNIO, Madrid - Spain IMI Europe s partnership for health > 5 bn 2.5 bn Partnership 2008-2020 Pharma industry 2.5 bn EU contribution from FP7
A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA
A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA Découpe 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s Patient centered, translational technology
1.0 Background to the organisation
1.0 Background to the organisation The National University of Ireland Galway, the Royal College of Surgeons in Ireland, University College Cork, University College Dublin and Trinity College and their
Christoph Bock ICPerMed First Research Workshop Milano, 26 June 2017
New Tools for Personalized Medicine *Tools = Assays, Devices, Software Christoph Bock ICPerMed First Research Workshop Milano, 26 June 2017 http://epigenomics.cemm.oeaw.ac.at http://biomedical-sequencing.at
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
Ottawa 4.0: Creating Global Market Advantage for Regional Impact. January 16 th, 2017
Ottawa 4.0: Creating Global Market Advantage for Regional Impact January 16 th, 2017 THE CHALLENGE SEIZING UNPRECEDENTED OPPORTUNITY Our Sectors Life Sciences Software Digital Media Communications Technology
NIHR Invention for Innovation Workshop. Leeds Clinical Research Facility Adding Value Debbie Beirne NIHR Leeds CRF Manager
NIHR Invention for Innovation Workshop Leeds Clinical Research Facility Adding Value Debbie Beirne NIHR Leeds CRF Manager Integrated R&I Model Surgical MedTech (MIC) CRF R&I In Vitro Diagnostics (MIC)
VIRTUAL DEMO DAY. Emerging Talent Acquisition Technologies SEPTEMBER 19, :00 PM EDT
VIRTUAL DEMO DAY Emerging Talent Acquisition Technologies SEPTEMBER 19, 2017 1:00 PM EDT MEET OUR MODERATOR PETER CLAYTON TOTALPICTURE MEDIA 2 INTRODUCING TALENT TECH LABS BRIAN DELLE DONNE PRESIDENT WHAT
Greenwood Genetic Center
Greenwood Genetic Center: The Center for Human Genetics and The Partnership Campus A Growing Collaborative South Carolina Community Development Association Steve Skinner, M.D. Greenwood Genetic Center
Laboratory Europe. Enter Cognitive Hub. Managing complexity within the Workplace of the Future
Laboratory Europe Enter Cognitive Hub Managing complexity within the Workplace of the Future Cognitive Hub Integrates AI services and cognitive capabilities to improve the way you work This scalable platform
Transform Clinical Research Into Value-Based Personalized Care
SAP Brief PUBLIC SAP Medical Research Insights Transform Clinical Research Into Value-Based Personalized Care SAP Brief Seamlessly combine clinical research with clinical routine Cutting-edge clinical
A New Era of Clinical Diagnostics: How the Business Model is Changing.
A New Era of Clinical Diagnostics: How the Business Model is Changing. Nancy J Kelley, President and CEO of Nancy J Kelley & Associates Remarks to BTIG Emerging Technologies in Healthcare Diagnostics September
S-BIOMEDIC. Company Profile
S-Biomedic is a Belgium based life science company exploring the unexploited cosmetic and therapeutic potential of the skin microbiome. The skin microbiome a habitat of billions of beneficial and harmful
NEXT BIG WAVE IN PHARMACEUTICAL INDUSTRY
SEPTEMBER 15, 2017 NEXT BIG WAVE IN PHARMACEUTICAL INDUSTRY Team Mavericks Smriti Mittal Pamela Mandal Harendra Prasad IIM Bangalore IIM Bangalore IIM Bangalore Smriti.mittal16@iimb.ernet.in pamela.mandal16@iimb.ernet.in
DIGITAL PATHOLOGY: TECHNOLOGIES AND GLOBAL MARKETS
DIGITAL PATHOLOGY: TECHNOLOGIES AND GLOBAL MARKETS HLC161A February 2014 Bhavna Joshi Project Analyst ISBN: 1-56965-706-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
Biomarkers as an emerging growth area in Denmark
Biomarkers as an emerging growth area in Denmark International Conference on Perspectives in Precision Medicine, Copenhagen March 1, 2018 Kim Holmstrøm, PhD. Chairman of The Danish Biomarker Network R&D
Industry 4.0: An industrial view
Industry 4.0: An industrial view Joerg Bauer President, GE Hungary 20 September 2017 Standard of Living in the last 2000 years 1850 years 150 years 2 GGO Europe Transformation 9/19/2017 Human Augmentation
THE CAMPAIGN FOR UC SANTA CRUZ THE GENOMICS INSTITUTE
THE CAMPAIGN FOR UC SANTA CRUZ THE GENOMICS INSTITUTE The promise of genomics to revolutionize medicine and to transform our understanding of life itself is one of the great opportunities of our time.
Promoting collaboration: Strategies and programs within health research and innovation
Promoting collaboration: Strategies and programs within health research and innovation Anne K Fahlvik, PhD, Executive director Mari K Nes, PhD, Special Adviser The Research Council of Norway The Research
How digital tools are improving access to healthcare (13 min read)
Published on Sandoz (https://www.sandoz.com) Home > Printer-friendly PDF > How digital tools are improving access to healthcare (13 min read) How digital tools are improving access to healthcare (13 min
Patent Analytics Research Report
SANGAMO THERAPEUTICS Patent Analytics Research Report May 2018 CRISPR IP assets Copy for IPStudies Corporate access Executive summary This research report specifically reviews the IP strategy and positioning
EBE White Paper on Personalised Medicine
EBE White Paper on Personalised Medicine EBE is a specialised group of European Federation of Pharmaceutical Industries and Associations, EFPIA Content p3 p4 p6 p6 p7 p9 p10 p11 p13 p14 Executive Summary
Personalized Healthcare Diagnostik und Therapie aus einer Hand
Personalized Healthcare Diagnostik und Therapie aus einer Hand Priv.-Doz. Dr. med. Christian Meisel DVFA Life Science Conference, 17 June 2009 1 The Challenge Personalised healthcare Roche s unique position
Paul Chang Senior Consultant, Data Scientist, IBM Cloud tw.ibm.com
Paul Chang Senior Consultant, Data Scientist, IBM Cloud paulyc@ tw.ibm.com 2 no AI without IA 3 3 3 3 3 3 AI Machine Learning Analytics Data The AI Ladder 3 Most are here Data Driven Insight Driven Digital
17th EHFG Electing Health The Europe We Want!
01 03 October 2014 17th EHFG Electing Health The Europe We Want! For more information about the final programme, speakers or the EHFG conference please contact us directly! Follow us on our social media
, ,
, 0 11201, 1000 1000 Top Cloud Technology Trends Cloud Security ML & AI Containers Hybrid Cloud Rapid growth in cloud adoption is driing the securing data, applications and workloads that now exist in
US Food and Drug Administration. Sandra L. Kweder, MD Deputy Director, Europe Office
US Food and Drug Administration Sandra L. Kweder, MD Deputy Director, Europe Office Basics Disclaimer The views in this presentation are my own I have no commercial involvement in any of these activities
Innovation and Technology in Breast Cancer 2018 A research initiative from Breast Cancer Foundation NZ.
Request for Proposals Innovation and Technology in Breast Cancer 2018 A research initiative from Breast Cancer Foundation NZ. Overview Breast Cancer Foundation NZ (BCFNZ) is committed to funding research
Introduction to IMI. Pierre Meulien Executive Director Innovative Medicines Initiative
Introduction to IMI Pierre Meulien Executive Director Innovative Medicines Initiative What is the Innovative Medicines Initiative? EU funding goes to: - universities - SMEs - patient groups etc 2.5 bn
Health Analytics in the Real World: Insights from 15 years of pan Canadian Health Information Data Warehousing and Digital Health perspectives
Health Analytics in the Real World: Insights from 15 years of pan Canadian Health Information Data Warehousing and Digital Health perspectives 1 Why are we here? Objective: Share Clinical Data Warehousing
OME 2013 summary of pitches
OME 2013 summary of pitches THEMES 1. data collection 2. data storage 3. data analysis & technology development 4. data use DATA COLLECTION Learning From Failure Bringing Me For You To Life Ninety-five
Regulatory Support to EU Research
Regulatory Support to EU Research OPEN INFO DAY Horizon 2020 'Health, demographic change and wellbeing Friday, 8 December 2017 Brussels Presented by Marisa Papaluca Senior Scientific Advisor, Scientific
LYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH. EN
LYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH EN www.lysarc.org THE LARGEST EUROPEAN ACADEMIC ORGANIZATION DEVOTED TO CLINICAL RESEARCH OPERATIONS IN THE LYMPHOMA FIELD Lymphoma is the 6th most
STRATEGIC PLAN
STRATEGIC PLAN 2014-2018 A LONG TERM VISION SERVING THE INNOVATION AND THE ECONOMIC DEVELOPMENT OF THE HEALTH INDUSTRY IN PARIS REGION 1 GOAL By the year 2020, the ambition of Medicen Paris Region is to
Against Lymphoma, I Take Action With LYSA.
Against Lymphoma, I Take Action With LYSA www.lysa-.org LYSA We are pleased to present LYSA (The Lymphoma Study Association), an academic cooperative group, which gathers every francophone medical team
BioProcess Technology Group. Helping Clients De-Risk Biopharmaceutical Development Since 1994
Helping Clients De-Risk Biopharmaceutical Development Since 1994 Who We Are The biopharmaceutical and biotherapeutic development experts We are a team of results-oriented professionals assisting clients